Who I am: BlairAs a firm, the team at KdT has decided to publish long-form Bio’s to help the folks we work with learn more about who we are as people. Our…May 21May 21
Expanding the Drug Delivery ToolboxToday our ability to treat many diseases is limited only by our ability to effectively deliver genetic medicines.Sep 15, 2022Sep 15, 2022
State of the Market: The GoalpostsBefore I start, let me get two things out of the way. First, in no way am I the caller of market tops and bottoms — and that’s not the…May 9, 2022May 9, 2022
The Bioproduction BattleThe globalization that began during the 1990s and flourished into this millennia reshaped aspects of our lives in ways we are only now…May 2, 2022May 2, 2022
How health insurance DAOs can break up RWD silosKdT has recently been exploring alternative data sharing incentive structures, since as a firm we believe the greatest advancements in…Feb 14, 2022Feb 14, 2022
Zymergen: A Cautionary TaleAs we continue to digest the news from Zymergen and its reverberations across the Synthetic Biology ecosystem, we wanted to take a moment…Aug 5, 2021Aug 5, 2021
The World in a Grain of SandContent is king (or so my kids tell me). We would like to be able to say that we have a grand plan in mind behind launching curated content…May 13, 2021May 13, 2021
What $50M in New Capital Means for EntrepreneursToday we’re announcing the closing of our $50M Fund II for KdT Ventures. With the announcement, one important aspect is obvious: with this…Mar 23, 2021Mar 23, 2021
Partnering and FocusN.B.- As a reminder, we are a seed-stage firm so our views relate to companies at that seed stage.Jan 26, 2021Jan 26, 2021
The Golden Age of Microfluidics?Lately, it feels like a disproportionately large number of companies we have seen at KdT deploy or manipulate microfluidic technology of…Jan 6, 2021Jan 6, 2021
